CRISPR Therapeutics (CRSP) P/B ratio

P/B ratio today
1.9×

CRISPR Therapeutics (CRSP) trades at 1.9× its book value per share at the end of fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/B ratio was 2.5×. That is 42.8% higher than the 1.7× of fiscal 2024. Figures as of 18 Nov 2026, 10:30 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

P/B ratio today
1.9×
P/B ratio, fiscal 2025
2.5×
Change on fiscal 2024
+42.8%
Highest on record
6.1×fiscal 2020
Lowest on record
1.7×fiscal 2022
Fiscal years on record
92017–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

CRISPR Therapeutics P/B ratio, in more detail

Today's figure is 23.4% below the fiscal 2025 year-end.

Across the 9 fiscal year-ends on record (2017–2025), the highest was 6.1× in fiscal 2020 and the lowest 1.7× in fiscal 2022. Today's P/B ratio is higher than at 22% of the 9 fiscal year-ends on record; their median is 2.6×.

History · 9 fiscal years

P/B ratio at each fiscal year-end

The last point is today's figure; the others are fiscal year-ends.

CRISPR Therapeutics P/B ratio, year by year

CRISPR Therapeutics (CRSP) P/B ratio by fiscal year
Fiscal yearP/B ratioChangeYear endedShare price at year-endBook value per share
Today1.9×—$40.15—
20252.5× 42.8% up$52.44$21.37
20241.7× 34.8% down$39.36$22.90
20232.6× 56.3% up$62.60$23.77
20221.7× 33.6% down$40.65$24.12
20212.5× 58.2% down$75.78$29.85
20206.1× 64.4% up$153.11$25.23
20193.7× 5.6% up$60.90$16.50
20183.5× 30.2% down$28.57$8.18
20175.0×—$23.48$4.69
2016——$20.26—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

The P/B ratio is the share price divided by book value per share — shareholders' equity on the balance sheet divided by the share count — at each fiscal year-end; a year with negative equity has no P/B.

How to read it

It compares the price with the accounting value of what the company owns net of what it owes, and matters most for banks, insurers and other balance-sheet businesses.

P/B ratio at health care companies of similar size

P/B ratio of CRISPR Therapeutics and comparable companies
CompanyP/B ratio
MiniMed Group MMED1.4×
Adaptive Biotechnologies ADPT21.1×
Heartflow HTFL13.8×
CRISPR Therapeutics CRSP2.0×
Travere Therapeutics TVTX42.7×
Option Care Health OPCH3.6×

Today's market value divided by shareholders' equity at the latest fiscal year-end. A company whose statements are in another currency than its shares is left out.

More on CRSP

CRISPR Therapeutics, figure by figure

CRISPR Therapeutics (CRSP) overview: price, valuation and scorecardAll health care companies by market value

CRISPR Therapeutics P/B ratio: questions and answers

What is CRISPR Therapeutics's P/B ratio?

CRISPR Therapeutics (CRSP) trades at 1.9× its book value per share at the end of fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/B ratio was 2.5×. That is 42.8% higher than the 1.7× of fiscal 2024.

Is CRISPR Therapeutics's P/B ratio high or low compared with its own history?

Today's P/B ratio is higher than at 22% of the 9 fiscal year-ends on record; their median is 2.6×.

What are the highest and lowest P/B ratio figures on record for CRISPR Therapeutics?

Across the 9 fiscal year-ends on record (2017–2025), the highest was 6.1× in fiscal 2020 and the lowest 1.7× in fiscal 2022.

How is CRISPR Therapeutics's P/B ratio calculated?

The P/B ratio is the share price divided by book value per share — shareholders' equity on the balance sheet divided by the share count — at each fiscal year-end; a year with negative equity has no P/B. For CRISPR Therapeutics it is on record here for 9 fiscal years, 2017 to 2025.

Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “CRISPR Therapeutics (CRSP) P/B ratio”, data as of 18 November 2026. https://funkfolio.com/stock/CRSP/pb-ratio

Underlying data: the company's filings with the SEC and Yahoo Finance.